No Data
No Data
Guangxi Wuzhou Zhongheng Group (600252.SH): Currently, there is no production of medicine for hemorrhoids.
Guangxi Wuzhou Zhongheng Group (600252.SH) stated on the interactive platform on July 5th that the company currently does not produce medication for hemorrhoids.
Guangxi Wuzhou Zhongheng Group (600252.SH): Cumulative capital of 121 million yuan repurchased 1.503% of shares.
On July 1st, Gelunhui announced that Guangxi Wuzhou Zhongheng Group (600252.SH) has repurchased a total of 51,875,400 shares of the company through the Shanghai Stock Exchange trading system by means of centralized bidding trading as of June 30, 2024, accounting for 1.5030% of the company's total share capital of 3,451,489,454 shares. The highest and lowest repurchase prices were 2.52 yuan/share and 2.12 yuan/share respectively, and the total amount paid was RMB 121,165,728.00 (excluding stamp duty, transaction fees and other transaction costs).
Guangxi Wuzhou Zhongheng Group (600252.SH): received a cash distribution of 16.11 million yuan from a subsidiary.
On July 1st, Gelunhui reported that Guangxi Wuzhou Zhongheng Group (600252.SH) has recently received a total of RMB 16,113,829.08 in cash distribution payments from its jointly-owned company Guangfa Xinde Zhongheng Huijin (Longyan) Equity Investment Partnership Enterprise (Limited Partnership) (referred to as Guangfa Xinde Fund).
The Five-year Earnings Decline Is Not Helping Guangxi Wuzhou Zhongheng GroupLtd's (SHSE:600252 Share Price, as Stock Falls Another 5.1% in Past Week
For many, the main point of investing is to generate higher returns than the overall market. But even the best stock picker will only win with some selections. So we wouldn't blame long term Guangxi
Guangxi Wuzhou Zhongheng Group (600252.SH) will distribute a dividend of 0.1 yuan per 10 shares in 2023, with the registration date on June 21st.
Guangxi Wuzhou Zhongheng Group (600252.SH) has issued an announcement that the company will implement annual equity distribution for 2023, at a ratio of 10 shares per...
Chongqing Lummy Pharmaceutical (300006.SZ): Qiu Yu and Guangxi Wuzhou Zhongheng Group have signed a "Voting Rights Proxy Agreement".
<表决权委托协议>Gelonghui, June 5, 丨 Laimei Pharmaceutical (300006.SZ) announced that shareholder Mr. Qiu Yu signed a “Supplementary Agreement” with the controlling shareholder Guangxi Wuzhou Zhongheng Group Co., Ltd. (“Zhongheng Group”) on April 7, 2023. The agreement will expire on June 7, 2024. On June 4, 2024, Mr. Qiu Yu and Zhongheng Group signed the “Voting Rights Entrustment Agreement”. The voting rights entrustment period is until June 7, 2026. The signing of this agreement will not lead to a change in the control of listed companies, nor will it trigger the “Administrative Measures on Acquisitions of Listed Companies”
No Data